Pacific Edge Ltd, the New Zealand-based cancer diagnostics firm behind the Cxbladder suite of tests, has secured $14.3M in new capital. The funding will bolster the company's global efforts in developing and commercializing its non-invasive genomic urine tests for bladder cancer.
Headquartered in Dunedin, Pacific Edge's Cxbladder tests are designed to improve patient experience and optimize clinical workflows by stratifying the risk of urothelial cancer. The tests, supported by over 20 years of research, are already available in the US, Australasia, Israel, and parts of Asia and South America, with Cxbladder Triage included in the American Urological Association’s Microhematuria Guideline.
%20(NZAX%3A%20CRP)%20(FSE%3A%20%203GRE).png&w=3840&q=75)
